Aromatase inhibitors better than tamoxifen at reducing the risk of breast cancer recurrence in women
Ovarian cancer therapy boosted by drug that slows disease’s advance
3 February 2022S. Korea extends COVID-19 rules amid post-holiday surge
4 February 2022Aromatase inhibitors better than tamoxifen at reducing the risk of breast cancer recurrence in women
A new study has shown that giving aromatase inhibitors instead of tamoxifen to premenopausal women with estrogen receptor positive (hormone-sensitive) breast cancer significantly reduces the risk of breast cancer recurrence. The results have been published today in The Lancet Oncology.
